<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775631</url>
  </required_header>
  <id_info>
    <org_study_id>CA186-017</org_study_id>
    <nct_id>NCT01775631</nct_id>
  </id_info>
  <brief_title>Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma</brief_title>
  <official_title>A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety, tolerability and maximum tolerated dose
      of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion
      (part 2) of study= Parallel Design
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities</measure>
    <time_frame>Up to 60 days after last dose of Urelumab</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Urelumab in combination with Rituximab as measured by incidence of adverse events (AEs), serious AEs, death, vital sign changes, electrocardiograms (ECGs), physical examination results, and laboratory test abnormalities</measure>
    <time_frame>Up to 110 days after last dose of Rituximab</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy-Antitumor Activity of Urelumab in combination with Rituximab as measured by best overall response, progression-free survival, time to response, and duration of response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of Urelumab and Rituximab</measure>
    <time_frame>12 time points up to Day 60 of Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of Urelumab</measure>
    <time_frame>12 time points up to Day 60 of Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Urelumab</measure>
    <time_frame>12 time points up to Day 60 of Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Cmin) of Urelumab and Rituximab</measure>
    <time_frame>12 + 9 time points up to Day 60 of Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) in one dosing interval (AUC(TAU)) of Urelumab</measure>
    <time_frame>12 time points up to Day 60 of Follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Urelumab in combination with Rituximab as determined by blood sample measurements of anti-drug antibodies (ADA)</measure>
    <time_frame>Up to approximately 110 days post study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>B-Cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Arm -1 - Urelumab + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) flat dose intravenous infusion on specified days
Rituximab intravenous flat dose infusion on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 - Urelumab + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) flat dose intravenous infusion on specified days
Rituximab intravenous flat dose infusion on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urelumab</intervention_name>
    <arm_group_label>Arm -1 - Urelumab + Rituximab</arm_group_label>
    <arm_group_label>Arm 1 - Urelumab + Rituximab</arm_group_label>
    <other_name>BMS-663513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Arm -1 - Urelumab + Rituximab</arm_group_label>
    <arm_group_label>Arm 1 - Urelumab + Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Clinical diagnosis of relapsed/refractory B-cell Malignancies (B-Non-Hodgkins Lymphoma
             (NHL)) per International Workshop Group (IWG)

          -  Progressed or refractory to at least 1 prior line of standard therapy

          -  Subjects in Expansion cohorts are restricted to relapsed/refractory diffuse large
             B-cell lymphoma (DLBCL) or Follicular Lymphoma (FL) subjects who are either relapsed
             or refractory to prior rituximab or ritxumab-containing chemotherapy regimens

          -  Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at screening
             and on treatment

          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 1

        Exclusion Criteria:

          -  Active or progressing brain metastases

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known Acquired immune
             deficiency syndrome (AIDS)

          -  History of any hepatitis (A, B or C)

          -  History of grade 3-4 drug-related hepatitis

          -  Known current drug or alcohol abuse

          -  Active tuberculosis (TB)

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti-CD137, Anti Cytotoxic T lymphocyte-associated
             antigen 4 (anti-CTLA4) or Anti-Glucocorticoid-induced tumor necrosis factor receptor
             (anti-GITR). However, Anti-Programmed Death-1 (anti-PD-1), Anti-Programmed
             Death-Ligand1 (anti-PD-L1) are permissible as prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucla Department Of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Iowa Hospitals And Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology And Hematology Care- Eastside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Of The University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia School Of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

